Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View.
Oprea-Lager DE, van Elst T, Aluwini S, Dewulf E, der Poel HV, Stoevelaar H, Bangma CH, Beeker A, Boudewijns S, Budiharto T, de Jong IJ, de Vries KC, Donswijk ML, Fütterer JJ, Hamberg P, Heijmen L, Hoekstra RJ, Kerkhofs TMA, Lavalaye J, Bruin DL, Noordzij W, Oving IM, Robbrecht DGJ, Schaake EE, van de Luijtgaarden ACM, van den Bergh RCN, van den Berkmortel F, van der Hulle T, van der Mijn JCK, van Dodewaard-de Jong JM, van Kruchten M, van Leeuwen PJ, van Limbergen E, van Moorselaar RJA, van Oort IM, van Roermund JGH, van Soest RJ, Veninga T, Vis AN, Voortman J, Willemse PM, Yakar D, Mehra N. Oprea-Lager DE, et al. Among authors: robbrecht dgj. Eur Urol Open Sci. 2025 Apr 7;75:69-79. doi: 10.1016/j.euros.2025.03.007. eCollection 2025 May. Eur Urol Open Sci. 2025. PMID: 40256661 Free PMC article.
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, Iivanainen S, Shetty S, Ma YT, Graham DM, Arora SP, Jaakkola P, Yap C, Xiang Y, Mandelin J, Karvonen MK, Jalkanen J, Karaman S, Koivunen JP, Minchom A, Hollmén M, Bono P. Rannikko JH, et al. Cell Rep Med. 2023 Dec 19;4(12):101307. doi: 10.1016/j.xcrm.2023.101307. Epub 2023 Dec 5. Cell Rep Med. 2023. PMID: 38056464 Free PMC article. Clinical Trial.
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.
Hansen AR, Gomez-Roca CA, Robbrecht DGJ, Verlingue L, Italiano A, Bauman JE, Steeghs N, Prenen H, Fayette J, Spicer J, Niu J, Habigt C, Schneider M, Evers S, Sleiman N, Dejardin D, Ardeshir C, Schmid D, Boetsch C, Charo J, Kraxner A, Teichgräber V, Keshelava N, Bonomi MR. Hansen AR, et al. Among authors: robbrecht dgj. Clin Cancer Res. 2024 Dec 16;30(24):5540-5547. doi: 10.1158/1078-0432.CCR-24-1562. Clin Cancer Res. 2024. PMID: 39422604 Free PMC article. Clinical Trial.
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.
Virtakoivu R, Rannikko JH, Viitala M, Vaura F, Takeda A, Lönnberg T, Koivunen J, Jaakkola P, Pasanen A, Shetty S, de Jonge MJA, Robbrecht D, Ma YT, Skyttä T, Minchom A, Jalkanen S, Karvonen MK, Mandelin J, Bono P, Hollmén M. Virtakoivu R, et al. Clin Cancer Res. 2021 Aug 1;27(15):4205-4220. doi: 10.1158/1078-0432.CCR-20-4862. Epub 2021 Jun 2. Clin Cancer Res. 2021. PMID: 34078651 Free PMC article. Clinical Trial.
[Symptomatic hypocalcaemia on denosumab use].
Baptista Lopes V, Robbrecht D, van Thiel S, van Guldener C. Baptista Lopes V, et al. Ned Tijdschr Geneeskd. 2013;157(29):A6159. Ned Tijdschr Geneeskd. 2013. PMID: 23859106 Dutch.
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.
Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SØ, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A. Robbrecht D, et al. Br J Cancer. 2022 Apr;126(7):1010-1017. doi: 10.1038/s41416-021-01657-7. Epub 2021 Dec 13. Br J Cancer. 2022. PMID: 34903842 Free PMC article. Clinical Trial.
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW. van der Wijngaart H, et al. Among authors: robbrecht dgj. Clin Cancer Res. 2021 Nov 15;27(22):6106-6114. doi: 10.1158/1078-0432.CCR-21-1104. Epub 2021 Sep 2. Clin Cancer Res. 2021. PMID: 34475104
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells.
Rijnders M, Balcioglu HE, Robbrecht DGJ, Oostvogels AAM, Wijers R, Aarts MJB, Hamberg P, van Leenders GJLH, Nakauma-González JA, Voortman J, Westgeest HM, Boormans JL, de Wit R, Lolkema MP, van der Veldt AAM, Debets R. Rijnders M, et al. Among authors: robbrecht dgj. Clin Cancer Res. 2022 Jan 1;28(1):215-226. doi: 10.1158/1078-0432.CCR-20-3319. Epub 2021 Oct 6. Clin Cancer Res. 2022. PMID: 34615720
Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer.
Mendelaar PAJ, Robbrecht DGJ, Rijnders M, de Wit R, de Weerd V, Deger T, Westgeest HM, Aarts MJB, Voortman J, Martens JWM, van der Veldt AAM, Nakauma-González JA, Wilting SM, Lolkema M. Mendelaar PAJ, et al. Among authors: robbrecht dgj. Mol Oncol. 2022 May;16(10):2086-2097. doi: 10.1002/1878-0261.13196. Epub 2022 Mar 17. Mol Oncol. 2022. PMID: 35181986 Free PMC article.
35 results